Rivulet Media Inc (fka RIVU)

[Canadian Trader]

SUMMARY OF DCELLVAX PROGRESS:

Feb 26, 2013 - BMSN announce Letter of Intent (LOI) to acquire WP Min cancer gene-silencing intellectual property.
http://ih.advfn.com/p.php?pid=nmona&article=56463068

Apr 4, 2013 - Update about pre-clinical and clinical programs; planned IND submission for Q4 2013.
http://ih.advfn.com/p.php?pid=nmona&article=57035344

May 6, 2013 - Regen officially acquires WP Min cancer gene-silencing therapy patent; will focus efforts on breast cancer.
http://ih.advfn.com/p.php?pid=nmona&article=57439657

Aug 8, 2013 - Regen licenses cancer gene-silencing therapy from Benitec BioPharma; demonstrates its action on IDO in dendritic cells.
http://ih.advfn.com/p.php?pid=nmona&article=58739425

Aug 16, 2013 - Conducting toxicity experiments using WP Min and Benitec technologies; reiterates planned submission of IND by Q4 2013.
http://ih.advfn.com/p.php?pid=nmona&article=58853168

Sept 17, 2013 - BMSN recruit Dr. David Suhy to Regen advisory board; his experience in RNAi is useful for Regen's cancer therapy.
http://ih.advfn.com/p.php?pid=nmona&article=59244933

Sept 25, 2013 - Announcement of "dCellVax" breast cancer immunotherapeutic product; outline further 8 months of milestones.
http://ih.advfn.com/p.php?pid=nmona&article=59354656

Jun 11, 2014 - Announce research paper on the use of gene-silencing in heart transplants, showing multiple applications of dCellVax technology; dCellVax IND planned for August 2014.
http://ih.advfn.com/p.php?pid=nmona&article=62529632

** All dates listed above refer to the date of the linked PR **

We can see from this timeline that Regen has carefully put together a unique approach for treating cancer by immunotherapy, based on the combination of technology obtained from WP Min and Benitec BioPharma. It is curious that they anticipated an IND submission in Q4 of 2013 as recent as August of last year, but you can see that the timeline gets more realistic once they recruited Dr. David Suhy (who, by the way, "was essential in the development of the gene-based hepatitis drug in collaboration with Pfizer"). It's nice see the June 11th dCellVax update, as it had been several months since they released anything about this product. We are only 35 calendar days out from the start of August, so I'm confident we'll see this IND actually submitted.

Can you believe that the cherry-on-top of the anticipated Regen BioPharma IPO and FDA approval of HemaXellerate I is a cancer immunotherapeutic?!

http://www.companiesandmarkets.com/News/Healthcare-and-Medical/US-cancer-vaccine-market-to-increase-at-a-CAGR-of-5-3/NI5300
"The cancer vaccine market is expected to grow from a 2010 value of US$12.8 billion, to US$17.4 billion by 2018. Approximately 1.5 million Americans are being diagnosed with cancer annually, and the annual overall cost of the disease is estimated to be $230 billion."

http://ih.advfn.com/p.php?pid=nmona&article=58853168
"By blocking the mechanisms by which the tumor escapes from the immune response, several companies have developed successful cancer drugs, for example, Bristol-Myers Squibb, which developed Ipilimumab which had 2012 sales of $706 million (3). Ipilimumab blocks the immune inhibitory molecule CTLA-4, which results in augmentation of immune responses."

For further Regen BioPharma timelines, please see my post on HemaXellerate I progress: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=102414215

$$ BMSN / Regen BioPharma $$